|
|
Conferences & Courses
|
Extracellular Biomarkers Summit
March 16-18, 2015 | Cambridge, MA
Cambridge Healthtech Institute’s Extracellular Biomarkers Summit (March 16-18, 2015 in Cambridge, MA) will provide timely coverage through four dedicated tracks: microRNA as Biomarkers and Diagnostics, Long Non-Coding RNA in Cancer, Exosomes and Microvesi
|
|
Protein & Antibody Engineering
March 31 - April 1, 2015 | Shanghai China
The field of protein engineering is at an exciting point in its development, with new generations of protein and antibody formats entering the market, improved understanding of structure-function relationships, and creative engineering that promises to op
|
|
Phage & Yeast Display
March 31 - April 1, 2015 | Shanghai China
Antibody generation, targeting membrane proteins, screening against challenging targets, generating novel constructs such as ADCs and bispecifics are all examples of today’s vast and important applications of screening and display technologies.
|
|
|
|
Life Science Media Library
|
Digital PCR Experiment Design and Primer DVD
October 6, 2014 |
The course will provide a broad overview of microfluidics as an enabling technology for point-of-care diagnostics. The course is constructed to provide a comprehensive overview of the field, starting with an introduction to microfluidics and its principles. Different manufacturing options will be discussed. Emphasis is put on the complete development process for commercial microfluidics-enabled POC-products, covering aspects of development strategies, application cases, markets as well as aspects of commercialization. The course covers the existing product landscape as well as exemplary disease cases with examples from molecular and immunodiagnostics. The course is suitable for scientists, technicians, engineers but also business developers who would like to develop a deeper understanding of microfluidics as a key technology for the development of new product in the POC markets
|
qPCR in Molecular Diagnostics
February 12, 2013 |
Quantitative real-time PCR is a valuable technology used for diagnostics of diseases such as cancer and infectious diseases, and for the detection of bacterial, fungal and viral pathogens. This course covers aspects of incorporating qPCR into standard molecular diagnosis including the challenges involved, an overview of the technology available, and next steps.
|
Integrating Human Factors Engineering (HFE) into Drug Delivery
January 22, 2013 |
In this DVD, we will provide a baseline understanding of the regulatory need, common practices and real world examples of integrating Human Factors Engineering into a drug development activity. Key topics to be addressed:
Why you should care: Regulatory expectations for the application of HFE
What to avoid: Right and wrong ways to apply HFE to your project
Lessons from the field: Real world examples of HFE
|
|
|
|
Publications, Reports, & Whitepapers
|
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
|
|
|
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.
|
Cancer Immunotherapy Report
Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies, published by Insight Pharma reports and written by Allan B. Haberman focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the works for cancer patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|